Genmab A/S/€GMAB
06:30
10:10
13:45
17:25
21:00
1D1W1MYTD1Y5YMAX
About Genmab A/S
Genmab A/S is a biotechnology company based in Copenhagen, Denmark, with a focus on developing innovative antibody therapeutics for the treatment of cancer. The company's core products include a range of proprietary technologies and therapeutic antibodies, most notably DARZALEX (daratumumab), which is used in the treatment of multiple myeloma. Genmab collaborates with various pharmaceutical companies to advance its research and expand its product offerings. Founded in 1999, the company leverages its proprietary antibody technologies, including the DuoBody and HexaBody platforms, to create differentiated therapies. Its strategic partnerships and emphasis on cutting-edge research provide it with a notable position in the biopharmaceutical industry.
Ticker
€GMAB
Sector
Primary listing
XGAT
Employees
2,681
Headquarters
Copenhagen, Denmark
Website
Genmab A/S Metrics
BasicAdvanced
€17B
12.57
€21.36
0.79
-
Price and volume
Market cap
€17B
Beta
0.79
52-week high
€286.90
52-week low
€154.81
Average daily volume
240
Financial strength
Current ratio
6.034
Quick ratio
6.015
Long term debt to equity
2.191
Total debt to equity
2.469
Interest coverage (TTM)
54.85%
Profitability
EBITDA (TTM)
1,253.257
Gross margin (TTM)
94.36%
Net profit margin (TTM)
41.17%
Operating margin (TTM)
36.87%
Effective tax rate (TTM)
11.03%
Revenue per employee (TTM)
€1,216,710
Management effectiveness
Return on assets (TTM)
13.38%
Return on equity (TTM)
29.41%
Valuation
Price to earnings (TTM)
12.572
Price to revenue (TTM)
5.148
Price to book
21.55
Price to tangible book (TTM)
33.97
Price to free cash flow (TTM)
15.3
Free cash flow yield (TTM)
6.54%
Free cash flow per share (TTM)
17.549
Growth
Revenue change (TTM)
23.36%
Earnings per share change (TTM)
121.26%
3-year revenue growth (CAGR)
26.87%
10-year revenue growth (CAGR)
41.25%
3-year earnings per share growth (CAGR)
23.11%
10-year earnings per share growth (CAGR)
36.08%
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by CBOE Europe and Deutsche Börse.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Genmab A/S stock?
Genmab A/S (GMAB) has a market cap of €17B as of December 16, 2025.
What is the P/E ratio for Genmab A/S stock?
The price to earnings (P/E) ratio for Genmab A/S (GMAB) stock is 12.57 as of December 16, 2025.
Does Genmab A/S stock pay dividends?
No, Genmab A/S (GMAB) stock does not pay dividends to its shareholders as of December 16, 2025.
When is the next Genmab A/S dividend payment date?
Genmab A/S (GMAB) stock does not pay dividends to its shareholders.
What is the beta indicator for Genmab A/S?
Genmab A/S (GMAB) has a beta rating of 0.79. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.